Crinetics Pharmaceuticals

In honor of the internet’s favorite trend, we asked our office dogs to describe themselves on LinkedIn. Swipe to see what they said ➡️ Think you’re a fit for our pack? We’re hiring: crinetics.com/careers/

We’re proud to share that a systematic literature review and network meta-analysis evaluating pharmacologic therapies in acromegaly has been accepted for publication in the Journal of Clinical Endocrinology & Metabolism. This milestone reflects our ongoing commitment to advancing scientific understanding and supporting the endocrine community.

This International Women’s Day, we’re recognizing the women who help drive mission, culture, and impact. Today, we’re proud to spotlight Adriana Cabré and her contributions to advancing our work in endocrinology. #InternationalWomensDay

BIO has appointed our CEO, Dr. Scott Struthers, to its Board of Directors. The board plays a key role in shaping policy and supporting scientific innovation across the global biotechnology community. Scott’s experience advancing therapies for endocrine diseases will contribute to those efforts and to BIO’s mission of improving patient outcomes worldwide. Congratulations to Scott, and thank you to BIO for your continued leadership in strengthening the biotech ecosystem.

Ready to help shape the future of endocrinology? Crinetics is seeking a Vice President, Clinical Endocrinology to play a pivotal role in advancing innovative therapies for patients living with endocrine diseases. If you’re passionate about translating science into meaningful impact for patients, we’d love to connect. Apply today: crinetics.com/careers

Every person with a rare disease has a story. This Rare Disease Day, take a moment to hear from others living with a rare disease like acromegaly: acromegalyreality.com

Today is Rare Disease Day. Living with a rare disease can mean uncertainty, long diagnostic journeys, and day-to-day impacts that aren’t always visible. While rare diseases affect many around the globe, too many voices go unheard. Today, we’re sharing patient perspectives to listen, learn, and stand with the rare disease community. #RareDiseaseDay To learn more about how we're supporting patients, visit crinetics.com/patients

As we wrap up Black History Month, Tony shares why awareness, representation, and self-advocacy are critical for people living with rare diseases. We’re proud to help elevate patient perspectives.

Next up on our Scientific Shorts Series: What is IGF-1, and how does it impact those with acromegaly? Watch Crinetics Chief Endocrinologist, Alan Krasner, M.D., explain the biology behind this serious endocrine disease and why early recognition is so important.

🎧 Behind the scenes with Crinetics leadership In a new Pituitary World News interview, Crinetics cofounders Scott Struthers and Stephen Betz reflect on the company’s journey, the science that drives our work, and the importance of advancing care in endocrinology. Listen to the full conversation: pituitaryworldnews.org/behind-the-sce…

Did you know? Acromegaly is caused by the chronic excess growth hormone, most often due to a benign tumor on the pituitary gland. At Crinetics, we’re driven to better understand endocrine diseases like acromegaly and the people living with them. Learn more about how we’re advancing innovation for serious endocrine diseases: bit.ly/3XghDQx

Kicking off our new Scientific Shorts series: a new series designed to break down big ideas in endocrinology. First up: What is the endocrine system? Watch Crinetics Chief Endocrinologist, Alan Krasner, M.D., explain how the endocrine system plays a critical role in everyday health and helps keep the body in balance.

The first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating our investigational, once-daily oral ACTH receptor antagonist in children and adolescents with classic CAH. We’re grateful to the patients, families, and clinical teams advancing this important research. Learn more here: bit.ly/49LB7kt

Join us today at 9:45 a.m. PT as we present a company update highlighting advancements from our deep endocrinology pipeline, which was purposefully built to improve the lives of people with endocrine diseases. Join the webcast: bit.ly/4pA3Ezm #JPM2026

We’re excited to join fellow leaders in the biotech and healthcare community at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Crinetics will highlight our significant achievements in 2025, share our outlook for 2026 and lay out our vision for 2030 during our corporate presentation on Tuesday, January 13 at 9:45 a.m. PT. Read more: bit.ly/49s6ikF

Today we announced new positive data from a Phase 2 trial of our investigative candidate to treat congenital adrenal hyperplasia. Results from Cohort 4 of this trial showed concurrent androstenedione lowering and glucocorticoid dose reduction in trial participants. More topline results from this cohort and an Open Label Extension study can be found here, alongside a commercial update from our commercial portfolio: bit.ly/4qJtoul

Big milestones. Bigger purpose. 2025 pushed our science, and our mission, further than ever. Watch the moments that shaped our year ⬇️

The first patient has been dosed in CALM-CAH, a pivotal study of our investigational candidate for classic congenital adrenal hyperplasia in adults – an important step forward in our mission to advance care for those living with serious endocrine diseases. 🔗 bit.ly/4rNXxKl

We’re proud to announce the first patient has been dosed in our Phase 1/2 trial evaluating our novel nonpeptide drug conjugate candidate CRN09682 for the treatment of neuroendocrine tumors and other somatostatin receptor 2-expressing tumors. Read the full announcement: bit.ly/3Mdcx48